The loose ends do not get smaller with repetition

Does a new study mean the old claim was right?

Only if it tests that claim. The DSIP fusion study in mice tested an engineered peptide in an induced insomnia model. I credit it with progress on that experimental problem; the native-DSIP sleep claims still need their own evidence. A changed molecule can be an advance and still leave the original question open.

Is a mechanism enough to predict a benefit?

The Semax gene-expression work in rats is a good reason to investigate what happens next. Better human cognition remains a separate outcome to measure. Likewise, GABA-related gene changes after Selank in rat cortex tell a different story from a patient’s anxiety score. I’m comfortable with the biological interest; the shortcut from mechanism to reliable benefit is where the argument breaks.

What is actually approved?

Semax and Selank have prescription-drug registration in Russia, and Semax in Ukraine. None of Semax, Selank or DSIP has an FDA- or EMA-approved indication; DSIP has no approved drug product. U.S. clinical prescribing depends on individual assessment. Compounded medicines are not FDA-approved. Research-labelled supply is a separate channel and does not establish pharmaceutical quality or human safety.

Can the accounts tell us how often something works?

Community reports are anecdotal accounts, not clinical evidence. They include perceived benefits, adverse experiences and non-response. There is no dependable denominator: the number who report publicly is not the number exposed, and the accounts do not separate expectation, product identity and a compound’s action. Safety needs a study, and incidence needs a measured figure; silence and enthusiasm supply neither.

Why no personal-use plan?

The early DSIP sleep pilot had six chronic insomniacs under study conditions. Rat experiments on the other compounds have their own models and routes. Those records cannot supply an individualized human dose or schedule.

Safety over long periods, interactions and effects in pregnancy or breastfeeding remain insufficiently characterized. Persistent anxiety, cognitive difficulties and sleep problems also require clinical evaluation. A literature site cannot assess a person’s symptoms or medicines.

What would be a meaningful next generation?

A named compound, a clearly described population, a repeatable outcome and safety follow-up long enough to address the claim. The newest paper can add something useful before all of those arrive. It simply has to be credited for the thing it added.

I’m impatient with promises of an upgrade and patient with an experiment that admits what it could not settle. Semax, Selank and DSIP all have unresolved questions worth pursuing. The reading list is where their differences become visible.